1. Scrip
  2. >>R&D

Cerevance’s First-In-Class Parkinson’s Candidate Shows Phase II Promise

CEO Predicts Annual Revenues Up To $1bn

 
• By Andrew McConaghie

Promising results from a small Phase II study will now propel the company’s CVN424 into pivotal trials, though its optimum dose is still unclear.

Parkinsons Drugs
The drug candidate could be used in combination with existing Parkinson's treatments, such as levadopa, but must first replicate the results in a larger pivotal study. • Source: Alamy

Cerevance has achieved Phase II trial success with its drug candidate reducing the time Parkinson’s disease patients spent in ‘Off time’ where symptoms recur despite medication.

More from R&D

More from Scrip

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By Kevin Grogan

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

Stock Watch: How Tariff Threat Might Boost Pharma Q1

 
• By Andy Smith

Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.

Merck’s Winrevair Slashes Morbidity-Mortality Risk For PAH Patients

 
• By Andrew McConaghie

The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.